Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ Transplantation, Ministry of Education, NHC Key Laboratory of Organ Transplantation, Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, China.
Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ Transplantation, Ministry of Education, NHC Key Laboratory of Organ Transplantation, Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, China.
Int Immunopharmacol. 2024 Nov 15;141:112793. doi: 10.1016/j.intimp.2024.112793. Epub 2024 Aug 14.
Renal transplantation is one of the primary approaches for curing end-stage kidney disease. With advancements in immunosuppressive agents, the short-term and long-term survival rates of transplanted kidneys have significantly improved. However, infections associated with potent immunosuppression have remained a persistent challenge. Among them, BK virus (BKV) reactivation following renal transplantation leading to BK virus-associated nephropathy (BKVAN) is a major cause of graft dysfunction. However, we still face significant challenges in understanding the pathogenesis, prevention, diagnosis, and treatment of BKVAN. These challenges include: 1. The mechanism of BKV reactivation under immunosuppressive conditions has not been well elucidated, leading to difficulties in breakthroughs in clinical research on prevention, diagnosis, and treatment. 2. Lack of proper identification of high-risk individuals, and effective personalized clinical management strategies. 3.Lack of early and sensitive diagnostic markers. 4. Lack of direct and effective treatment options due to the absence of specific antiviral drugs. The purpose of this review is to summarize the current status and cutting-edge advancements in BKV-related research, providing new methods and perspectives to address future research challenges.
肾移植是治疗终末期肾病的主要方法之一。随着免疫抑制剂的进步,移植肾的短期和长期存活率有了显著提高。然而,与强效免疫抑制相关的感染仍然是一个持续存在的挑战。其中,肾移植后 BK 病毒(BKV)再激活导致 BK 病毒相关性肾病(BKVAN)是移植物功能障碍的主要原因。然而,我们在理解 BKVAN 的发病机制、预防、诊断和治疗方面仍然面临重大挑战。这些挑战包括:1. 免疫抑制条件下 BKV 再激活的机制尚未得到很好的阐明,导致在预防、诊断和治疗的临床研究方面难以取得突破。2. 缺乏对高危个体的适当识别,以及有效的个性化临床管理策略。3. 缺乏早期和敏感的诊断标志物。4. 由于缺乏特异性抗病毒药物,缺乏直接有效的治疗选择。本综述的目的是总结 BKV 相关研究的现状和最新进展,为解决未来的研究挑战提供新的方法和视角。